NCT02650986: Gene-Modified T Cells in Treating Patients With Locally Advanced or Stage IV Solid Tumors Expressing NY-ES0-1

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: ESO, HLA
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: 

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Tumors must be HLA-A*0201 positivefor all cohorts & NY-ESO-1+ for cohort 4 only
Exclusions: Patients with known clinically active brain metastases- see trial for details

Comments are closed.

Up ↑